ICU Medical Reports Q4 Loss and Revenue Growth

ICU Medical reveals its Q4 results amid losses. The company reported an EPS of -$0.97, reflecting financial struggles. Despite a revenue increase to $629.81 million, projected losses for fiscal 2025 raise concerns for investors.

Date: 28-02-2025

AI Rating: 4

Earnings Per Share (EPS): ICU Medical reported a significant loss of -$0.97 in Q4, compared to -$0.71 in the same quarter last year. This decline indicates worsening financial performance, which could negatively impact investor sentiment.

Revenue Growth: The company did report some positive news with revenue increasing to $629.81 million in Q4, up from $587.86 million in the prior year. However, this increase may not be enough to offset concerns related to losses reported.

Net Income and Future Projections: The company anticipates a net loss for the fiscal year 2025, ranging from $45 million to $28 million. This projection, alongside expected losses per share between $1.81 and $1.11, heightens investor uncertainty and may lead to negative stock movements.

Profit Margins and Free Cash Flow: The report does not provide specific details concerning profit margins or free cash flow for ICU Medical, which could offer more insight into their operational efficiency and financial health.

Return on Equity (ROE): The analysis lacks information regarding ROE, making it difficult to gauge the company's ability to generate returns relative to shareholder equity.

Stocks: ICUI